News

A six-week program, called vibration training — in which people stand on a vibrating platform for short periods of time — eased disability and improved cognitive abilities and quality of life in people with multiple sclerosis (MS), a small randomized study found. The program was also well accepted and…

The National Multiple Sclerosis Society invested more than $8.7 million over the summer to support 29 new training fellowships, early career research awards, and other initiatives aiming to advance multiple sclerosis (MS) research and care. Awarded research projects align with the society’s Pathways to Cures Roadmap: stopping disease activity and…

  An extended-release formulation of amantadine, ADS-5102 was significantly more effective than a placebo at increasing walking speed in multiple sclerosis (MS) patients who had difficulty with this, particularly younger patients with a shorter disease course, the INROADS Phase 3 trial demonstrated. Further clinical work on this investigative…

Getting the Pfizer-BioNTech vaccine for COVID-19 does not increase the risk of multiple sclerosis (MS) relapses in the two months following vaccination, according to a new study. The results support recommending COVID-19 vaccines for people with MS, its researchers said. “The incidence of relapses in the 2 months before and…

Experiencing serious infections during adolescence is tied to an increased risk of developing multiple sclerosis (MS) later in life, but those occurring in childhood don’t increase MS risk, according to a new Swedish study. The study also found that certain types of infections, especially those that affect the central…

A blood test for serum neurofilament light chain (sNfL) levels, along with radiological findings, can help to detect early cognitive issues in people recently diagnosed with multiple sclerosis (MS), a study suggests. The study “Cortical Thickness and Serum NfL Explain Cognitive Dysfunction in Newly Diagnosed Patients…

A new service, Bionews Clinical is seeking to bring more patients into relevant clinical trials by helping all involved — scientists, pharmaceutical companies, people with diseases — regard these studies as part of continuing care. “Today what happens is that the conversation about patients participating in a clinical trial is…

Belong.Life has launched an app that allows health professionals to build and manage their own online communities of multiple sclerosis (MS) patients. Called i-Belong – Connecting Communities, the app offers to healthcare providers, pharmaceuticals, and patient advocacy and other groups a platform to effectively and efficiently educate…

The Adira Foundation is inviting people with neurodegenerative diseases and their caregivers to join a grant proposal review committee. A nonprofit foundation, its mission is to unite people affected by some of most common neurodegenerative diseases — namely, multiple sclerosis, amyotrophic lateral sclerosis, Alzheimer’s disease, Huntington’s disease, and…

Though 13 may be an unlucky number for some, that was not the case for the 13th Annual A&W Canada “Burgers to Beat MS Day.” The initiative raised $1.4 million, bringing the total for the 13-year run to more than $17 million. On Aug. 19, every A&W Teen Burger…

In people with early-stage multiple sclerosis (MS), the presence of high levels of neurofilament light chain (sNfL) protein in the bloodstream combined with thinning of the retina is a strong indicator of future disease activity, a recent study demonstrates. “Our findings encourage the application of both sNfL and retinal…

The U.S. Food and Drug Administration (FDA) has agreed to review ANI Pharmaceuticals’ supplemental new drug application for the approval of Cortrophin Gel to treat people with multiple sclerosis (MS) and other chronic inflammatory conditions, including rheumatoid arthritis. Purified Cortrophin Gel (repository corticotropin injection USP) is a purified…

People with relapsing-remitting multiple sclerosis (RRMS) in Sweden have lower rates of worsening disability than those who live in Denmark, likely due to differences in treatment strategies in each country, according to a new study. “This study shows that, for the first time to our knowledge, differences in national…

A real-world study confirmed the effectiveness and safety of interferon beta-1b in treating older adults with multiple sclerosis (MS), those over the age of 40. “These findings from a real-world setting are promising and demonstrate the positive benefit-risk ratio for [interferon beta-1b] in this study population of middle-aged and…

Moderate-to-severe bowel dysfunction was detected in 14.5% of adult people with multiple sclerosis (MS), an Italian study reports. The prevalence of bowel dysfunction was increased in women and in patients with progressive forms of MS, higher disability, older age, and longer disease duration. Despite the prevalence of bowel dysfunction…

A new clinical trial launched by the National Institutes of Health (NIH) is evaluating the impact of an extra dose of an approved or authorized COVID-19 vaccine in people with multiple sclerosis (MS) and other autoimmune diseases who did not properly respond to an original vaccine regimen. Approximately 600 people will…

Landos Biopharma has entered into a research partnership with Johns Hopkins University School of Medicine focused on advancing LABP-66 as a potential oral, once-daily therapy for multiple sclerosis (MS) and other disorders, the company announced. LABP-66 is a lab-made molecule that activates NLRX1, a receptor that is key in…

Most people with multiple sclerosis (MS) in the U.S. have health insurance, but many lack important other types of insurance, such as life insurance, short-term disability insurance, and long-term care insurance, according to an online survey of patients. Its findings suggest that MS patients who are likely to be…

Blocking a particular receptor protein of the BMP signaling pathway effectively promoted the maturation of myelin-producing cells and myelin repair in two mouse models of multiple sclerosis (MS), a study showed. Notably, these benefits, observed even after disease onset, took place in the presence of fibrinogen, a blood clotting…

As the federal election looms in Canada, a nation that has one of the world’s highest rates of multiple sclerosis (MS), the MS Society of Canada is urging patients and advocates to inform candidates about issues of importance to the MS community. The letter-writing and social media campaign,…

People newly diagnosed with clinically isolated syndrome (CIS) or multiple sclerosis (MS) frequently experience pain, fatigue, depression, and anxiety in the first year after diagnosis, a new study finds. Fatigue was reported by almost two-thirds of new patients, and half experienced pain. Many individuals experienced multiple symptoms simultaneously,…

The Multiple Sclerosis Association of America (MSAA) is inviting people to participate in its Improving Lives Through Art Series, a cycle of virtual fundraising events starting Sept. 14. The kick-off event of this four-part fall series is a virtual follow-along painting experience. Tickets can be purchased here…

Ocrevus (ocrelizumab) reduces relapse risk and slows disability progression in multiple sclerosis (MS) but also is associated with higher hospitalization rates in older people with relapsing forms of the disease, a new observational study reports. Hospitalizations — which occurred mainly due to urinary tract infections — were more frequent…

D.C. United and its official sponsor, Leidos, opened a campaign to donate up to $20,000 to the National Multiple Sclerosis (MS) Society, the soccer team announced. The initiative aims to support the almost one million people in the U.S. living with multiple sclerosis (MS). Among them is…

A new research project, funded by the National Institutes of Health (NIH), aims to better understand how different types of cells in the nervous system — specifically neurons and glia cells — communicate with each other and ultimately affect both motor and non-motor functions. Its findings may have important implications…

The National Multiple Sclerosis Society will host the second edition of its Black MS Experience Summit, a virtual event to help forge connections among those who understand the experience of living with multiple sclerosis (MS) as a Black person. Register here to join the interactive, two-day…

NervGen Pharma announced that its Phase 1 clinical trial evaluating the safety and pharmacological properties of NVG-291 — its lead therapeutic candidate for multiple sclerosis (MS) and other neurologic conditions — in healthy volunteers is going according to plan, with early top-line data expected later this year. “The…

A variation in a gene called STK11, previously shown to increase the risk for multiple sclerosis (MS) among Caucasians, is now also linked to a greater likelihood of MS in Black people. In fact, the variation was significantly more common in Black MS patients with secondary progressive MS (SPMS),…

Sativex (nabiximols), a cannabis-based oral spray approved in the U.K. to ease spasticity — or muscle stiffness and spasms — in adults with multiple sclerosis (MS), remains unavailable to many patients there, according to a report by the MS Society UK. Sativex is the only licensed…

PoNS, a non-invasive devise to accompany physical therapy in multiple sclerosis (MS) patients with difficulty walking, will be available on the U.S. market early next year, its developer, Helius Medical Technologies, announced in a quarterly financial update. Short for Portable Neuromodulation Stimulator, the PoNS…